Document Type
Article
Publication Date
2-4-2025
Abstract
Background: An immune checkpoint inhibitor (ICI) backbone is a standard of care for frontline metastatic clear cell renal cell carcinoma, involving either ICI doublet or tyrosine kinase inhibitor (TKI) with ICI. These phase 3 trials used a sunitinib control arm. The optimal regimen is uncertain. Objective: To compare long-term responders of these trials using extended follow-up data stratified by International Metastatic RCC Database Consortium risk group. Methods: Phase 3 trial data (CheckMate 214, KEYNOTE-426, CheckMate 9ER, and CLEAR) with a minimum follow-up of four years was used. Pseudo individual patient data (IPD) was obtained from Kaplan-Meier curves using the graph digitizer software IPDfromKM R package to extract coordinates of points on the curves and to apply a numerical algorithm to reconstruct progression-free survival (PFS) and overall survival (OS) results. Durable response (DR) was defined as PFS ≥ 24 months, extreme durable response (EDR) as PFS ≥ 36 months, and long-term OS as OS ≥ 48 months. Results: For the favorable risk group, lenvatinib-pembrolizumab had the highest DR and EDR, while ipilimumab-nivolumab had the lowest DR, and cabozantinib-nivolumab had the lowest EDR; there was no difference in long-term OS among the regimens (p = 0.11). For the intermediate/poor risk group, lenvatinib-pembrolizumab also had the highest DR and EDR compared to other regimens with similar DR and EDR; there was also no difference in long-term OS among the regimens (p = 0.22). Conclusion: TKI-ICI was overall associated with higher DR and EDR regardless of risk status compared to ICI doublet. Yet, OS at 48 months were similar when stratified by favorable versus intermediate/poor risk.
Recommended Citation
Jang, Albert; Zhong, Jeffrey Y.; Kumar, Hamsa L.S.; Zarrabi, Kevin K.; Zhu, Alec; Grier, Abby L.; Calaway, Adam; Shoag, Jonathan E.; Bukavina, Laura; Jia, Angela Y.; Mendiratta, Prateek; Sheng, Iris Y.; Rao, Santosh; Brown, Jason R.; Garcia, Jorge A.; Margevicius, Seunghee; Fu, Pingfu; and Barata, Pedro C., "Durable Responses to Immune Checkpoint Inhibitor-Based Regimens for Metastatic Clear Cell Renal Cell Carcinoma Stratified by Imdc Risk Groups: A Pooled Analysis of Four Randomized Phase 3 Trials" (2025). Department of Medical Oncology Faculty Papers. Paper 299.
https://jdc.jefferson.edu/medoncfp/299
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Language
English
Included in
Chemical Actions and Uses Commons, Diagnosis Commons, Investigative Techniques Commons, Neoplasms Commons, Oncology Commons
Comments
This article is the author's final published version in Kidney Cancer, Volume 9, 2025, Article number 24684570241311419.
The published version is available at https://doi.org/10.1177/24684570241311419.
Copyright © The Author(s) 2025